A Study to Evaluate the Efficacy of Botulinum Toxin in Patients With Hidradenitis Suppurativa

This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease hidradenitis suppurativa (HS). In this study, the investigators will extend data from a 12-week pilot study to rigorously test the hypothesis that botulinum toxin (BoNT) therapy reduces disease severity and relieves HS pain symptoms..

NCT Number	NCT07756346
Lead Sponsor	University of Massachusetts, Worcester Collaborators: Emory University
Conditions	Hidradenitis Suppurativa (HS)
Enrollment	40 participants
Start Date	2026-10
Primary Completion	2028-09 (estimated)
Study Completion	2029-04 (estimated)
Updated on ClinicalTrials.gov	2026-08-10